Viking Therapeutics, INC

Viking Therapeutics reported strong progress in its Q2 2026 results, with key obesity drug trials fully enrolled and advancing, alongside a robust cash position.

Viking Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Viking Therapeutics announced its Q4 and full-year 2025 financial results, alongside significant progress in its obesity drug pipeline, including plans for Phase 3 trials for oral VK2735 and ongoing subcutaneous VK2735 studies.

Viking Therapeutics reported its third quarter 2025 financial results, highlighting significant progress in its obesity drug pipeline with VK2735 subcutaneous and oral formulations, despite increased net losses.

Viking Therapeutics announced positive top-line Phase 2 results for its oral VK2735 tablet, demonstrating statistically significant weight reductions in obesity patients.

Viking Therapeutics announced its second quarter 2025 financial results, highlighting the initiation of Phase 3 trials for subcutaneous VK2735 in obesity and completion of enrollment for the oral VK2735 Phase 2 study, alongside increased net losses.

Viking Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026, detailing financial performance, ongoing clinical trials, and strategic updates.

Viking Therapeutics, Inc. reported its first quarter 2026 financial results, highlighting significant increases in research and development expenses and a substantial cash balance.

Viking Therapeutics reported significantly increased R&D expenses and net losses in Q3 2025, driven by the advancement of its VK2735 programs into Phase 3 and positive Phase 2 oral results, while maintaining a strong cash position.

Viking Therapeutics reported significant progress in its clinical pipeline, initiating Phase 3 trials for its obesity drug VK2735 and revealing positive 52-week histologic data for its NASH candidate VK2809, alongside increased R&D expenses and a strong cash position.

Viking Therapeutics reports its financial results for the first quarter of 2025, emphasizing ongoing clinical trials and strategic manufacturing agreements.

Viking Therapeutics' third quarter 2024 report details increased R&D spending, a net loss, and a strong cash position to fund operations through at least 2025.

Viking Therapeutics reports significant clinical progress for its metabolic and endocrine disorder pipeline, including positive Phase 2 results for oral and subcutaneous VK2735 in obesity and VK2809 in NASH/MASH, alongside Phase 3 initiations.

Viking Therapeutics' 2024 10-K filing highlights clinical advancements in VK2735 and VK2809, alongside financial stability for continued development.

Viking Therapeutics' 10-K filing details the company's clinical advancements, financial standing, and future strategies in developing therapies for metabolic and endocrine disorders.

Brian Lian, President & CEO and a Director of Viking Therapeutics, Inc., sold 148,517 shares of common stock on July 28, 2026 for $33.32 per share.

Greg Zante, Chief Financial Officer of Viking Therapeutics, Inc., sold 21,217 shares of common stock on July 28, 2026 for $33.47 per share.

Marianna Mancini, Chief Operating Officer of Viking Therapeutics, Inc., sold 18,217 shares of common stock on July 28, 2026 for $33.47 per share.

Viking Therapeutics Chief Medical Officer Hubert C. Chen was granted 190,000 stock options as part of an equity incentive.

Viking Therapeutics' Chief Commercial Officer, Neil William Aubuchon, was granted 180,000 stock options with an exercise price of $31.76, vesting over four years.

Viking Therapeutics' CFO, Greg Zante, reported the acquisition of substantial equity awards and subsequent tax-related share sales.

Viking Therapeutics, Inc. announces its 2026 Annual Meeting of Stockholders to elect directors, ratify auditors, and approve executive compensation.

Viking Therapeutics will hold its annual stockholder meeting virtually on May 20, 2025, to vote on director elections, auditor ratification, and executive compensation.

Viking Therapeutics files an amendment to its proxy statement to reflect the appointment of CBIZ CPAs P.C. as the new independent registered public accounting firm for the fiscal year ending December 31, 2025, following Marcum LLP's resignation.

Viking Therapeutics will hold its annual stockholder meeting virtually on June 13, 2023, to vote on director elections, auditor ratification, executive compensation, and an amendment to the company's certificate of incorporation.

Viking Therapeutics will hold its annual stockholders meeting virtually on May 20, 2025, to vote on director elections, auditor ratification, and executive compensation.

Viking Therapeutics will hold its annual stockholder meeting virtually on June 13, 2023, to vote on director elections, auditor ratification, executive compensation, and an amendment to the company's certificate of incorporation.

Vanguard Capital Management has reported beneficial ownership of 5.08% of Viking Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group reported a 0% beneficial ownership in Viking Therapeutics Inc. following an internal realignment.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Viking Therapeutics Inc. as of September 30, 2025.

FMR LLC and Abigail P. Johnson have reported an 8.7% beneficial ownership stake in Viking Therapeutics Inc. common stock as of June 30, 2025.

FMR LLC and its affiliates, along with Abigail P. Johnson, have filed an amended Schedule 13G, reporting a beneficial ownership of 10.0% of Viking Therapeutics Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.5% beneficial ownership stake in Viking Therapeutics, Inc. as of March 31, 2025.